Eli Lilly

News

Lilly's tau drug for Alzheimer's flunks phase 2 test

Eli Lilly is still celebrating the FDA approval of its amyloid-directed Alzheimer's therapy Kisunla but has had less fortune with a candidate against tau, another well-established drug targ

News

Lilly says tirzepatide supply issues are resolving

Eli Lilly has raised its revenue guidance for 2024 by $3 billion, after reporting strong growth for tirzepatide in diabetes and obesity, fuelled by the end of supply constraints for startin

News

Novo Nordisk chief executive Lars Fruergaard Jørgensen

Wegovy slowdown rattles Novo Nordisk investors

Shares in Novo Nordisk have gone into reverse after it reported weaker-than-expected sales of obesity therapy Wegovy, raising concerns among investors about growing competition in the categ

News

Lilly gets first heart outcomes readout with tirzepatide

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefi

News

After EU setback, Eisai/Biogen build case for Leqembi

Eisai and Biogen have reported data showing that the benefit of treatment with their Alzheimer's disease therapy Leqembi appears to build over time, with no increase in safety risks.

News

Innovent throws its hat further into China's GLP-1 ring

Innovent Biologics is planning a second filing for its dual GLP-1/glucagon agonist mazdutide in China, as it tries to carve out a share of a market currently dominated by Novo Nordisk and E

Lilly's tau drug for Alzheimer's flunks phase 2 test

Lilly says tirzepatide supply issues are resolving

Wegovy slowdown rattles Novo Nordisk investors

Lilly gets first heart outcomes readout with tirzepatide

After EU setback, Eisai/Biogen build case for Leqembi

Innovent throws its hat further into China's GLP-1 ring

Threat of Trump's pharma tariffs looms again

Using AI-driven synthetic personas to take your insights fur...

Eli Lilly

Editor's Picks